Combining NLRP3/GSDMD inhibitors with NET/MET modulators may reduce inflammation, microthrombosis, and multiorgan failure in sepsis and COVID-19, provided it is applied within the optimal therapeutic window, guided by biomarkers and adaptive precision clinical trials (82, 83). The gene discussed is NLRP3; the disease is COVID-19.